Main › Compare › CJC-1295 vs MK-677 (Ibutamoren)
A side-by-side comparison from PeptideSciences101, the open peptide reference.
Overview
CJC-1295 and MK-677 (Ibutamoren) are both performance & growth peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares CJC-1295 and MK-677 (Ibutamoren) across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
CJC-1295 MK-677 (Ibutamoren) Category Performance & Growth Performance & Growth Regulatory status (US) Research use only Research use only Typical dosage 1-2 mg 10-25 mg Frequency weekly daily Reported benefits Increased muscle mass, fat loss, improved recovery, better sleep, enhanced bone density Increased appetite, muscle growth, improved sleep, bone density enhancement Reported side effects Water retention, joint pain, potential insulin resistance with prolonged use Increased appetite, water retention, elevated blood sugar, potential insulin resistance
Key differences
Primary use. CJC-1295 is categorised under Performance & Growth, while MK-677 (Ibutamoren) falls under Performance & Growth. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. CJC-1295: not FDA-approved; treated as a research compound. MK-677 (Ibutamoren): not FDA-approved; treated as a research compound.
Dosing. CJC-1295 is typically dosed at 1-2 mg (weekly). MK-677 (Ibutamoren) is typically dosed at 10-25 mg (daily).
Can you stack them?
Some protocols combine peptides, but stacking CJC-1295 and MK-677 (Ibutamoren) has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
What is the difference between CJC-1295 and MK-677 (Ibutamoren)? CJC-1295 and MK-677 (Ibutamoren) are both performance & growth peptides, but they differ in mechanism, dosing, and regulatory status. CJC-1295 is not FDA-approved; generally classified as a research compound, whereas MK-677 (Ibutamoren) is not FDA-approved; generally classified as a research compound.
What is CJC-1295 used for? Growth hormone, muscle mass, fat loss.
What is MK-677 (Ibutamoren) used for? Oral GH secretagogue.
Can you take CJC-1295 and MK-677 (Ibutamoren) together? Some users combine peptides within a single protocol, but stacking CJC-1295 and MK-677 (Ibutamoren) has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
Is CJC-1295 or MK-677 (Ibutamoren) FDA-approved? CJC-1295 is not FDA-approved; generally classified as a research compound. MK-677 (Ibutamoren) is not FDA-approved; generally classified as a research compound.
Read the full articles
CJC-1295 — full monograph: mechanism, research, dosing & references MK-677 (Ibutamoren) — full monograph: mechanism, research, dosing & references
More Performance & Growth comparisons
CJC-1295 compared across categories
← All peptide comparisons
© 2026 PeptideSciences101 · Content licensed for educational reference
Educational reference only. Nothing on this site constitutes medical advice. Consult a licensed healthcare professional.